Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISIONARY: Phase 3 Trial of Sibeprenlimab in IgA Nephropathy
2022-500079-30-00Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Sibeprenlimab with Placebo (2 arms). Primary endpoint: Primary Efficacy: Ratio of uPCR at 9 months compared with baseline. Started Aug 2022; status: completed.
02
Drugs
sibeprenlimab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2022-500079-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500079-30-00.